Second- and third-line therapy in gastric cancer/new options for therapy

被引：0
|
作者：
Schmalenberg, H. [1 ]
机构：
[1] Krankenhaus Dresden Friedrichstadt, Med Klin 4, Dresden, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V435
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [21] Third-Line Therapy in Metastatic Colorectal Cancer
    van de Haar, Joris
    Valeri, Nicola
    Voest, Emile E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 190 - 191
  • [22] Third-line therapy for metastatic colorectal cancer
    M. G. Gundgaard
    J. B. Soerensen
    E. Ehrnrooth
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 1 - 13
  • [23] Third-line therapy for metastatic colorectal cancer
    Gundgaard, M. G.
    Soerensen, J. B.
    Ehrnrooth, E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 1 - 13
  • [24] Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies
    Rass, K.
    Tadler, D.
    Tilgen, W.
    HAUTARZT, 2006, 57 (09): : 773 - +
  • [25] Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    Retz, Margitta
    Steiner, Thomas
    AKTUELLE UROLOGIE, 2021, 52 (05) : 425 - 426
  • [26] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [27] Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
    Oh, Yun
    Herbst, Roy S.
    Burris, Howard
    Cleverly, Ann
    Musib, Luna
    Lahn, Michael
    Bepler, Gerold
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1135 - 1141
  • [28] A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
    Kang, Yoon-Koo
    Muro, Kei
    Ryu, Min-Hee
    Yasui, Hirofumi
    Nishina, Tomohiro
    Ryoo, Baek-Yeol
    Kamiya, Yukimasa
    Akinaga, Shiro
    Boku, Narikazu
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 355 - 361
  • [29] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [30] Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy
    Busch, Martin
    Ruester, Christiane
    Schinkoethe, Claudia
    Gerth, Jens
    Wolf, Gunter
    CLINICAL NEPHROLOGY, 2013, 80 (02) : 105 - 113
12345